Lidocaine for systemic sclerosis: a double-blind randomized clinical trial.

ABSTRACT:

Background

Systemic sclerosis (scleroderma; SSc) is an orphan disease with the highest case-specific mortality of any connective-tissue disease. Excessive collagen deposit in affected tissues is a key for the disease's pathogenesis and comprises most of the clinical manifestations. Lidocaine seems to be an alternative treatment for scleroderma considering that: a) the patient's having excessive collagen deposits in tissues affected by scleroderma; b) the patient's demonstrating increased activity of the enzyme prolyl hydroxylase, an essential enzyme for the biosynthesis of collagen; and c) lidocaine's reducing the activity of prolyl hydroxylase. The aim of this study was to evaluate the efficacy and safety of lidocaine in treating scleroderma.

Methods

A randomized double-bli

SUBMITTER: Riera R 

PROVIDER: S-EPMC3041650 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature